If you’ve ever said, “Patents Don’t Really Matter” or “I’ll deal with my IP later,” you may want to think again. Apple has dominated the global smartwatch market since it released its Apple Watch with a diversified smartwatch line-up across various price points. Apple has set the market with its premium model, the Apple Ultra, which debuted at $799 USD. Per the November 4Q meeting, Apple’s Wearables, Home, and Accessories revenue generated $9.3 Billion of Apple’s $83.5 Billion revenue and $23 Billion profit. So why on earth would Apple announce they’re suspending sales of one of their best-selling Apple Watch products? What on earth would make them pull a best-selling product from Apple stores and online Apple shopping carts during the biggest holiday season of the year, before Christmas?
It’s because….
Patents do matter!!
Discover the unexpected twists in the Apple saga as the tech giant announces the suspension of sales for its flagship Apple Watch Series 9 and Apple Watch Ultra 2 in the U.S. In this article, we unveil five lesser-known facets of the ITC ruling and its impact on Apple’s wearable empire.
5 Things You Didn’t Know About the ITC Ruling
Key Points:
1. ITC Ruling and Patent Dispute:
The ITC ruling, stemming from a longstanding patent dispute with medical technology company Masimo, has far-reaching consequences for Apple’s latest smartwatches. Masimo claims that specific patents infringe on their patented technology, that sparked this legal battle.The ITC ruling, centered around a dispute on the Apple Watch’s blood oxygen sensor technology, mandates a halt in sales for the affected models.The dispute has its roots in Masimo’s claims that Apple infringed on several of its patents related to blood oxygen monitoring.
The essence of the claims is that Apple hired away several of Masimo’s key engineers, in some cases doubling their salaries to get them to produce similar technology to Masimo’s wearable tech. In addition, Masimo filed a legal appeal after several of their medical device patents were challenged by Apple in a number of proceedings before the U.S.P.T.O. argued before the Patent Trial and Appeal Board (PTAB) and the Inter Partes Review (IPR).
An inter partes review (IPR) is a procedure for challenging the validity of a United States patent before the United States Patent and Trademark Office. More specifically, the inter partes review is a trial proceeding conducted at the Board to review the patentability of one or more claims in a patent only on a ground that could be raised under §§ 102 or 103, and only on the basis of prior art consisting of patents or printed publications.
Prior to the passage of the Leahy-Smith America Invents Act (AIA) by Congress and signed into law by President Barack Obama on September 16, 2011, patent validity used to require a jury trial within the District Courts. The inter partes review (IPR) process allows the PTAB to hold a hearing with the respective parties and make its decision based on evidence presented before the PTAB. Appeals to a PTAB’s decision are heard by the United States Court of Appeals for the Federal Circuit.
In this case, Masimo filed before the United States Court of Appeals for the Federal Circuit as the Appellant, with Apple as the Appellee. Masimo argued five counts. The U.S. C.A.F.C. affirmed four counts and reversed one count relating to non-obviousness. This is the decision on September 12, 2023 has now passed a sixty-day presidential review period and must be implemented prior to penalty.
2. Sales Suspension Details:
The sales suspension decision sets specific dates when Apple Watch Series 9 and Ultra 2 will no longer be available for purchase from Apple’s official channels.So what is the ITC order’s immediate impact on in-store inventory and online sales? Apple Watch Series 9 and Ultra 2 will cease to be available for purchase on Apple’s website and retail locations in the U.S. from December 21 and December 24, respectively.The ITC order restricts the import of these models to the U.S. after December 25.
3. Presidential Review Period:
The ITC ruling is subject to a 60-day Presidential Review Period, with a potential impact on Apple’s ability to sell the affected models. Apple has chosen to preemptively comply with the ITC’s decision while expressing disagreement and exploring legal options. The Presidential Review Period is fast approaching the deadline, which has forced Apple to pull one of its best-selling Apple Watch products to comply with this decision.
4. Implications and Apple’s Perspective:
Apple highlights the ITC’s impact on suppliers, consumers, and the broader economy, emphasizing the life-saving features of the Apple Watch.The company also contends that Masimo’s litigation is an attempt to boost its own smartwatch launch.
While these arguments didn’t help Apple win the ITC decision, they may prove useful in the future.
5. Future Scenarios and Unknowns:
As Apple navigates the complexities of this unprecedented development, the future of Apple Watch Series 9 and Ultra 2 sales remains uncertain. The company plans to file an appeal, exploring potential settlements, licensing agreements, and design adjustments. The ITC ban underscores the legal challenges in the evolving landscape of wearable technology. Apple is playing hardball by not negotiating with Masimo for a licensing deal or other IP sharing agreement to prevent them from having to pull its best-selling product from the shelves during the prime holiday shopping season. Only time will tell if this is the right move for Apple.
Conclusion
As the tech world watches closely, this article sheds light on five crucial aspects that add complexity to the Apple Watch Series 9 and Ultra 2 saga. The unfolding legal drama highlights the challenges and uncertainties in the ever-evolving landscape of wearable technology. I’m going to continue digging into the public case files, legal documents, and transcripts if/when they are made available. Based on the information researched to craft this article, this seems to be more about poor IP strategy than anything else.
Poaching an engineering or design team, then launching a competing product with the same or similar technology is going to definitely raise the ire of your competition. You can guarantee an infringement lawsuit will be filed. Apple pursued patent invalidation of Masimo’s patents agressively via IPR filings at the PTAB. Masimo, appealed to the U.S. C.A.F.C. and the decision was rendered September 12, 2023.
Appeal has expressed plans to appeal. If this is upheld on appeal, there may be damages awarded going back years. This is why we teach you the IP strategy along with patent protection. With Apple’s deep pockets, this may have been an intentional gamble or a calculated risk. With their record-breaking profits made off of wearables, they can afford to pay for any damages and still be profitable.
What do you think? Was this a willful infringement by Apple? Was this just a case of a smaller company trying to get a pound of flesh from Apple? Let me know your thoughts in the comments. I am interested in hearing from you, IP litigators. Also, patent holders and tech executives, what are your thoughts? Could your IP strategy and IP portfolio stand up to this type of test? Are you sure?
Anyhow, this demonstrates, in no uncertain terms, that PATENTS MATTER! IP Strategy Matters! Intellectual property matters! Your intellectual property strategy matters!
Is your intellectual property protected? Will your IP strategy and IP portfolio stand up to this type of test? Are you sure? To make sure, schedule a consultation with our office or call 1-800-840-8372.